Re: higher AUC after bolus compared to infusion?

From: Jeffrey . a . Wald Date: December 04, 2008 technical Source: mail-archive.com
Volume and AUC are independent - AUC is defined by dose and clearance. You have stated that your estimate of Vss is not impacted so your experimental design is probably capturing enough of the PK profile to describe the underlying phenomenon. I think the best starting point is a michaelis-menten model with diminished clearance at high plasma concentrations. Regards, Jeff ______________________________________________________ Jeff Wald, PhD jeffrey.a.wald 'at' gsk.com Director, Clinical Pharmacology Modeling and Simulation RTP, NC P Please consider the ENVIRONMENT before printing this mail P [EMAIL PROTECTED] Sent by: [EMAIL PROTECTED] 04-Dec-2008 04:02 To [email protected], [EMAIL PROTECTED] cc Subject [NMusers] higher AUC after bolus compared to infusion? Dear all, I have trouble modeling some rat PK data obtained after intravenous dosing. I have dense data for two different doses, given either as bolus, half-hour or 3-hour infusion. We know that the compound has a large binding affinity to intracellular structures and therefore has a high volume of distribution (~100L/kg in rats). However, what we observed in the mentioned study is that the AUC after bolus dosing is ~3 times higher than after infusions (no difference between 0.5 and 3 h), and this was observed for both dose groups (effect a bit less pronounced for high dose, but still there). Noncompartmental analysis indicates that this is due to lower clearance and not a change in Vss. At the moment I have no idea what kind of model would capture an observation like this. Has anybody ever observed something like this, and even better, have some ideas on model coding? Any ideas would be welcome! Best regards Nele _________________________________________ Bayer Schering Pharma AG Development Pharmacokinetics Berlin, S109, 03, 306A Phone: +49 30 468-15146 Fax: +49 30 468-11527 E-mail: [EMAIL PROTECTED] Web: http://www.bayerscheringpharma.de Vorstand: Andreas Fibig, Vorsitzender | Werner Baumann, Andreas Busch, Ulrich Köstlin, Kemal Malik, Bernd Metzner, Gunnar Riemann Vorsitzender des Aufsichtsrats: Werner Wenning Sitz der Gesellschaft: Berlin | Eintragung: Amtsgericht Charlottenburg HRB 283 B
Dec 04, 2008 Nele Mueller-Plock higher AUC after bolus compared to infusion?
Dec 04, 2008 Nele . Plock higher AUC after bolus compared to infusion?
Dec 04, 2008 Jeffrey.a.wald Re: higher AUC after bolus compared to infusion?
Dec 04, 2008 Saik Urien Svp Re: higher AUC after bolus compared to infusion?
Dec 04, 2008 Malaz Abutarif Re: higher AUC after bolus compared to infusion?
Dec 04, 2008 Jeffrey . a . Wald Re: higher AUC after bolus compared to infusion?